ADAM33

Human gene encoding the protein ADAM33

ADAM33

Symbol	ADAM33
HGNC ID	240
Alternative symbols	–
Entrez Gene	80332
OMIM	607114
RefSeq	NM_025220
UniProt	Q9BZ11
Chromosome	20p13
Locus supplementary data	–

ADAM33 is a gene that encodes a member of the ADAM (a disintegrin and metalloprotease) family of proteins. These proteins are involved in a variety of biological processes, including cell signaling, adhesion, and migration. ADAM33 has been implicated in the pathogenesis of asthma and other respiratory diseases.

Structure

The ADAM33 gene is located on chromosome 20 at the p13 band. It consists of 22 exons and spans approximately 14 kilobases. The protein encoded by ADAM33 is a type I transmembrane protein with a signal peptide, a pro-domain, a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and a cytoplasmic tail.

Function

ADAM33 is involved in the remodeling of the extracellular matrix and has been shown to play a role in the development and repair of lung tissue. The protein's metalloprotease domain is responsible for its proteolytic activity, which can cleave and activate or inactivate other proteins. The disintegrin domain is thought to mediate cell-cell and cell-matrix interactions.

Clinical Significance

ADAM33 has been associated with asthma susceptibility. Genetic studies have identified several single nucleotide polymorphisms (SNPs) in the ADAM33 gene that are linked to an increased risk of developing asthma. These polymorphisms may affect the expression or function of the ADAM33 protein, leading to altered airway remodeling and inflammation.

Research has also suggested a role for ADAM33 in other respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and bronchial hyperresponsiveness.

Research Directions

Ongoing research is focused on understanding the precise mechanisms by which ADAM33 contributes to asthma and other respiratory diseases. This includes studies on the regulation of ADAM33 expression, the identification of its substrates, and the development of potential therapeutic interventions targeting ADAM33 activity.

Also see

• Asthma
• Chronic obstructive pulmonary disease
• Metalloprotease
• Gene expression